busulfan has been researched along with Congenital Immunodeficiency Disease in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of our study was to compare the safety and efficacy of hematopoietic cell transplantation (HCT) using fludarabine (Flu)-based reduced intensity conditioning (RIC) with busulfan (BU) or melphalan (Mel) for primary immunodeficiency diseases (PID)." | 8.02 | Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases. ( Aoki, Y; Ashiarai, M; Endo, A; Hiroki, H; Hoshino, A; Ichimura, T; Imai, K; Inoue, K; Inoue, M; Ishiwata, Y; Isoda, T; Kajiwara, M; Kamiya, T; Kanegane, H; Kawahara, Y; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Miyawaki, R; Mizutani, S; Morio, T; Nagasawa, M; Nishimura, A; Okano, T; Okawa, T; Ono, S; Ono, T; Takagi, M; Tanaka-Kubota, M; Tezuka, M; Tomizawa, D; Tomoda, T; Ueyama, J; Yamagishi, C; Yamashita, M; Yanagimachi, M; Yasuhara, M, 2021) |
| "We report three adult patients with primary immunodeficiency (PID) treated with reduced-intensity allogenic hematopoietic cell transplantation (HCT) with fludarabine/treosulfan conditioning and graft-versus-host disease (GvHD) prophylaxis with alemtuzumab and a calcineurin inhibitor." | 4.12 | Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series. ( Arranto, C; Dalla Via, V; Heim, D; Junker, T; Matteazzi, F; Medinger, M; Passweg, JR; Recher, M; Stelmes, A; van den Berg, J, 2022) |
| "The purpose of our study was to compare the safety and efficacy of hematopoietic cell transplantation (HCT) using fludarabine (Flu)-based reduced intensity conditioning (RIC) with busulfan (BU) or melphalan (Mel) for primary immunodeficiency diseases (PID)." | 4.02 | Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases. ( Aoki, Y; Ashiarai, M; Endo, A; Hiroki, H; Hoshino, A; Ichimura, T; Imai, K; Inoue, K; Inoue, M; Ishiwata, Y; Isoda, T; Kajiwara, M; Kamiya, T; Kanegane, H; Kawahara, Y; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Miyawaki, R; Mizutani, S; Morio, T; Nagasawa, M; Nishimura, A; Okano, T; Okawa, T; Ono, S; Ono, T; Takagi, M; Tanaka-Kubota, M; Tezuka, M; Tomizawa, D; Tomoda, T; Ueyama, J; Yamagishi, C; Yamashita, M; Yanagimachi, M; Yasuhara, M, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dalla Via, V | 1 |
| Stelmes, A | 1 |
| Recher, M | 1 |
| Arranto, C | 1 |
| Junker, T | 1 |
| Matteazzi, F | 1 |
| Heim, D | 1 |
| Passweg, JR | 1 |
| Medinger, M | 1 |
| van den Berg, J | 1 |
| Yu, ZP | 1 |
| Ding, JH | 1 |
| Sun, AN | 1 |
| Chen, BA | 1 |
| Ge, Z | 1 |
| Wu, DP | 1 |
| Dimitrova, D | 1 |
| Gea-Banacloche, J | 1 |
| Steinberg, SM | 1 |
| Sadler, JL | 1 |
| Hicks, SN | 1 |
| Carroll, E | 1 |
| Wilder, JS | 1 |
| Parta, M | 1 |
| Skeffington, L | 1 |
| Hughes, TE | 1 |
| Blau, JE | 1 |
| Broadney, MM | 1 |
| Rose, JJ | 1 |
| Hsu, AP | 1 |
| Fletcher, R | 1 |
| Nunes, NS | 1 |
| Yan, XY | 1 |
| Telford, WG | 1 |
| Kapoor, V | 1 |
| Cohen, JI | 1 |
| Freeman, AF | 1 |
| Garabedian, E | 1 |
| Holland, SM | 1 |
| Lisco, A | 1 |
| Malech, HL | 1 |
| Notarangelo, LD | 1 |
| Sereti, I | 1 |
| Shah, NN | 1 |
| Uzel, G | 1 |
| Zerbe, CS | 1 |
| Fowler, DH | 1 |
| Gress, RE | 1 |
| Kanakry, CG | 1 |
| Kanakry, JA | 1 |
| Lum, SH | 1 |
| Hoenig, M | 1 |
| Gennery, AR | 1 |
| Slatter, MA | 1 |
| Al-Mofareh, M | 1 |
| Ayas, M | 1 |
| Al-Seraihy, A | 1 |
| Siddiqui, K | 1 |
| Al-Jefri, A | 1 |
| Ghemlas, I | 1 |
| Alsaedi, H | 1 |
| El-Solh, H | 1 |
| Al-Sweedan, S | 1 |
| Al-Saud, B | 1 |
| Al-Mousa, H | 1 |
| Al-Dhekri, H | 1 |
| Arnaout, R | 1 |
| Mohammed, R | 1 |
| Al-Muhsen, S | 1 |
| Al-Ahmari, A | 1 |
| Nishimura, A | 1 |
| Aoki, Y | 1 |
| Ishiwata, Y | 1 |
| Ichimura, T | 1 |
| Ueyama, J | 1 |
| Kawahara, Y | 1 |
| Tomoda, T | 1 |
| Inoue, M | 1 |
| Matsumoto, K | 1 |
| Inoue, K | 1 |
| Hiroki, H | 1 |
| Ono, S | 1 |
| Yamashita, M | 1 |
| Okano, T | 1 |
| Tanaka-Kubota, M | 1 |
| Ashiarai, M | 1 |
| Miyamoto, S | 1 |
| Miyawaki, R | 1 |
| Yamagishi, C | 1 |
| Tezuka, M | 1 |
| Okawa, T | 1 |
| Hoshino, A | 1 |
| Endo, A | 1 |
| Yasuhara, M | 1 |
| Kamiya, T | 1 |
| Mitsuiki, N | 1 |
| Ono, T | 1 |
| Isoda, T | 1 |
| Yanagimachi, M | 1 |
| Tomizawa, D | 1 |
| Nagasawa, M | 1 |
| Mizutani, S | 1 |
| Kajiwara, M | 1 |
| Takagi, M | 1 |
| Kanegane, H | 1 |
| Imai, K | 1 |
| Morio, T | 1 |
1 review available for busulfan and Congenital Immunodeficiency Disease
| Article | Year |
|---|---|
Conditioning Regimens for Hematopoietic Cell Transplantation in Primary Immunodeficiency.
Topics: Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Primary Immunod | 2019 |
1 trial available for busulfan and Congenital Immunodeficiency Disease
| Article | Year |
|---|---|
Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 2020 |
4 other studies available for busulfan and Congenital Immunodeficiency Disease
| Article | Year |
|---|---|
Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series.
Topics: Adult; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mal | 2022 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul | 2019 |
Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphohisti | 2020 |
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
Topics: Busulfan; Child, Preschool; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cel | 2021 |